Yıl 2017, Cilt 17 , Sayı 4, Sayfalar 146 - 150 2017-10-01

Subcutaneous Immunoglobulin Use in Children
Çocuklarda Subkutan İmmünglobülin Kullanımı

Manolya ACAR [1] , Ayper SOMER [2]


Human plasma derived immunoglobulin products have been considered among treatment options for many of the disor- ders, particularly primary immune deficiencies. Immunoglobulins can be administered either intravenous IV , subcutaneous SC or intramuscular IM route. In recent years, SCIG use has been preferred increasingly because of higher patient comfort, with decreased systemic side effects and costs. Up-to-date information regarding SCIG use in pediatric patients is being summarized in this review
İnsan plazma kaynaklı immünglobülinler başta primer immün yetersizlik hastalıkları olmak üzere pek çok hastalı- ğın tedavi seçenekleri arasında yer almaktadır. İmmünglobülin preparatları; intravenöz IV , subkutan SC ya da intramüsküler IM yolla verilebilir. Son yıllar- da subkutan immünglobülin SIG uygulaması, hasta konfo- runun daha yüksek, maliyetinin ve yan etki insidansının daha düşük olması nedeniyle tercih edilmektedir. Bu yazıda çocuk hastalarda SIG kullanımı ile ilgili güncel bilgiler özetlenmiştir
  • Bruton oc. Agammaglobulinemia. Pediatrics 1952;9:722-8.
  • Jolles S. Subcutaneous and intramuscular immune globulin therapy. www.uptodate.com.
  • Janeway CA, Apt l, Gitlin D. Agammaglobulinemia. Trans Assoc Am Physicians 1953;66:200-2.
  • Gitlin D, Janeway CA. Agammaglobulinemia: conge- nital, acquired and transient forms. Prog Hematol 1956;1:318-56.
  • Hill lE, Mollison Pl. MRC working party on hypo- gammaglobulinemia, collection of cases and design of trial, Chap. II, Hypogammaglobulinemia in the UK. Her Majesty’s Stationery Office: London, 1971: pp. 4-8.
  • Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am 2008;28:779.
  • https://doi.org/10.1016/j.iac.2008.07.002
  • Stiehm ER. Adverse effects of human immunoglobu- lin therapy. Transfus Med Rev 2013;27:171.
  • https://doi.org/10.1016/j.tmrv.2013.05.004
  • Berger M. Subcutaneous IgG in neurologic diseases. Immunotherapy 2014;6:71-83.
  • https://doi.org/10.2217/imt.13.146
  • Bourque PR, Pringle CE, Cameron W, Cowan J, Chardon JW. Subcutaneous immunoglobulin therapy in the chronic management of myasthenia gravis: A retrospective cohort study. PLoS One 2016;11: e0159993.
  • https://doi.org/10.1371/journal.pone.0159993
  • Misbah SA, Baumann A, Fazio R, Dacci P, Schmidt DS, Burton J, Sturzenegger M. A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglo- bulin therapy: an open-label proof-of-concept study. J Peripher Nerv Syst 2011;16:92-7.
  • https://doi.org/10.1111/j.1529-8027.2011.00330.x
  • US Food and Drug Administration (FDA) approval: http://www.fda.gov/biologicsbloodvaccines/bloodblo- odproducts/approvedproducts/licensedproductsblas/ fractionatedplasmaproducts/ucm414117.htm (Accessed on September 19, 2014).
  • Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol 2010; 30:734.
  • https://doi.org/10.1007/s10875-010-9423-4
  • Ochs HD, Gupta S, Kiessling P, et al. Safety and efficacy of self-administered subcutaneous immunog- lobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006;26:265.
  • https://doi.org/10.1007/s10875-006-9021-7
  • Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. Bio Drugs 2007;21:105.
  • https://doi.org/10.2165/00063030-200721020-00005
  • Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a revi- ew of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117:S525.
  • https://doi.org/10.1016/j.jaci.2006.01.015
  • Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 2008;28:803.
  • https://doi.org/10.1016/j.iac.2008.06.006
  • Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in pati- ents with primary immunodeficiencies. Clin Immunol 2011;139:133.
  • https://doi.org/10.1016/j.clim.2011.01.006
  • Waniewski J, Gardulf A, Hammarström l. Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunode- ficiency. J Clin Immunol 1994;14:90.
  • https://doi.org/10.1007/BF01541341
  • Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in pati- ents with primary immunodeficiencies. Clin Immunol 2011;139:133.
  • https://doi.org/10.1016/j.clim.2011.01.006
  • Huang F, Feuille E, Cunningham-Rundles C. Home care use of intravenous and subcutaneous immunoglo- bulin for primary immunodeficiency in the United States. J Clin Immunol 2013;33:49.
  • https://doi.org/10.1007/s10875-012-9776-y
  • Kobrynski l. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodefici- ency diseases. Biologics 2012;6:277-87.
  • https://doi.org/10.2147/BTT.S25188
  • Jolles S, Orange JS, Gardulf A, et al. Current treat- ment options with immunoglobulin G for the individu- alization of care in patients with primary immunodefi- ciency disease. Clin Exp Immunol 2015;179:146.
  • https://doi.org/10.1111/cei.12485
  • Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008;122:210.
  • https://doi.org/10.1016/j.jaci.2008.04.044
  • Gardulf A, nicolay U, Asensio O, et al. Rapid subcu- taneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies- -a prospective, multi-national study. J Clin Immunol 2006;26:177.
  • https://doi.org/10.1007/s10875-006-9002-x
  • Markvardsen lH, Christiansen I, Andersen H, Jakobsen J. Headache and nausea after treatment with high-dose subcutaneous versus intravenous immuno- globulin. Basic Clin Pharmacol Toxicol 2015;117:409- 12.
  • https://doi.org/10.1111/bcpt.12428
  • Epstein JS, Zoon KC. Dear doctor letter - important drug warning: immune globulin intravenous (human). FDA Med Watch. US Food and Drug Administration; 1998.
  • Pierce lR, Jain n. Risks associated with the use of intravenous immunoglobulin. Transfusion Med Rev 2003;17:241-51.
  • https://doi.org/10.1016/S0887-7963(03)00038-5
  • Fasth A, nystrom J. Safety and efficacy of subcutane- ous human immunoglobulin in children with primary immunodeficiency. Acta Paediatrica 2007;96:1474-8.
  • https://doi.org/10.1111/j.1651-2227.2007.00485.x
  • Sundin U, nava S, Hammarstrom l. Induction of unresponsiveness against IgA in IgA- deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol 1998;112:341-6.
  • https://doi.org/10.1046/j.1365-2249.1998.00571.x
  • Karakoç Aydıner E, Kıykım A, Barıs S, Özen A, Barlan I. Use of subcutaneous immunoglobulin in primary immune deficiencies. Turk Pediatri Ars 2016;51:8-14.
  • https://doi.org/10.5152/TurkPediatriArs.2016.3058
  • Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei n. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody defi- ciencies: systematic review and meta-analysis. J Clin Immunol 2012;32:1180-92.
  • https://doi.org/10.1007/s10875-012-9720-1
  • Bonilla FA, Duff C. Subcutaneous Immunoglobulin Replacement. Immune Deficiency Foundation: Clinical Focus 2015;16:1-16.
Birincil Dil tr
Bölüm Research Article
Yazarlar

Yazar: Manolya ACAR
Kurum: İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Çocuk Enfeksiyon Hastalıkları Bilim Dalı

Yazar: Ayper SOMER
Kurum: İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Çocuk Enfeksiyon Hastalıkları Bilim Dalı

Tarihler

Yayımlanma Tarihi : 1 Ekim 2017

Bibtex @ { jchild799954, journal = {Çocuk Dergisi}, issn = {1302-9940}, eissn = {1308-8491}, address = {Çocuk Dergisi Yayın Kurulu Sekreterliği İstanbul Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı Çapa, 34390, İstanbul}, publisher = {İstanbul Üniversitesi}, year = {2017}, volume = {17}, pages = {146 - 150}, doi = {10.5222/j.child.2017.146}, title = {Çocuklarda Subkutan İmmünglobülin Kullanımı}, key = {cite}, author = {Acar, Manolya and Somer, Ayper} }
APA Acar, M , Somer, A . (2017). Çocuklarda Subkutan İmmünglobülin Kullanımı . Çocuk Dergisi , 17 (4) , 146-150 . DOI: 10.5222/j.child.2017.146
MLA Acar, M , Somer, A . "Çocuklarda Subkutan İmmünglobülin Kullanımı" . Çocuk Dergisi 17 (2017 ): 146-150 <https://dergipark.org.tr/tr/pub/jchild/issue/56918/799954>
Chicago Acar, M , Somer, A . "Çocuklarda Subkutan İmmünglobülin Kullanımı". Çocuk Dergisi 17 (2017 ): 146-150
RIS TY - JOUR T1 - Çocuklarda Subkutan İmmünglobülin Kullanımı AU - Manolya Acar , Ayper Somer Y1 - 2017 PY - 2017 N1 - doi: 10.5222/j.child.2017.146 DO - 10.5222/j.child.2017.146 T2 - Çocuk Dergisi JF - Journal JO - JOR SP - 146 EP - 150 VL - 17 IS - 4 SN - 1302-9940-1308-8491 M3 - doi: 10.5222/j.child.2017.146 UR - https://doi.org/10.5222/j.child.2017.146 Y2 - 2020 ER -
EndNote %0 Çocuk Dergisi Çocuklarda Subkutan İmmünglobülin Kullanımı %A Manolya Acar , Ayper Somer %T Çocuklarda Subkutan İmmünglobülin Kullanımı %D 2017 %J Çocuk Dergisi %P 1302-9940-1308-8491 %V 17 %N 4 %R doi: 10.5222/j.child.2017.146 %U 10.5222/j.child.2017.146
ISNAD Acar, Manolya , Somer, Ayper . "Çocuklarda Subkutan İmmünglobülin Kullanımı". Çocuk Dergisi 17 / 4 (Ekim 2017): 146-150 . https://doi.org/10.5222/j.child.2017.146
AMA Acar M , Somer A . Çocuklarda Subkutan İmmünglobülin Kullanımı. Çocuk Dergisi. 2017; 17(4): 146-150.
Vancouver Acar M , Somer A . Çocuklarda Subkutan İmmünglobülin Kullanımı. Çocuk Dergisi. 2017; 17(4): 146-150.
IEEE M. Acar ve A. Somer , "Çocuklarda Subkutan İmmünglobülin Kullanımı", Çocuk Dergisi, c. 17, sayı. 4, ss. 146-150, Eki. 2017, doi:10.5222/j.child.2017.146